Dynavax Technologies Corporation
General ticker "DVAX" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $1.4B (TTM average)
Dynavax Technologies Corporation does not follow the US Stock Market performance with the rate: -8.5%.
Estimated limits based on current volatility of 1.9%: low 10.74$, high 11.16$
Factors to consider:
- Total employees count: 405 as of 2024
- US accounted for 95.6% of revenue in the fiscal year ended 2024-12-31
- Top business risk factors: Regulatory and compliance, Intellectual property risks, Labor/talent shortage/retention, Operational and conduct risks, Cybersecurity threats
- Earnings for 9 months up through Q3 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [10.40$, 16.55$]
- 2025-12-31 to 2026-12-31 estimated range: [10.45$, 16.68$]
Financial Metrics affecting the DVAX estimates:
- Positive: with PPE of 71.3 at the end of fiscal year the price was very low
- Positive: -3.60 < Operating profit margin, % of -1.46
- Negative: negative Industry operating cash flow (median)
- Positive: 41.86 < Shareholder equity ratio, % of 60.51 <= 63.39
- Negative: Inventory ratio change, % of 1.58 > 0.84
- Negative: 0.01 < Interest expense per share per price, % of 0.41
- Positive: 1.87 < Return on assets ratio (scaled to [-100,100]) of 2.69
- Negative: Operating cash flow per share per price, % of 3.98 <= 6.82
- Positive: Industry inventory ratio change (median), % of -1.41 <= -0.15
- Negative: Investing cash flow per share per price, % of -1.08 <= -0.66
Short-term DVAX quotes
Long-term DVAX plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $723.68MM | $233.28MM | $277.25MM |
| Operating Expenses | $440.16MM | $270.31MM | $281.37MM |
| Operating Income | $283.52MM | $-37.03MM | $-4.12MM |
| Non-Operating Income | $10.78MM | $32.66MM | $34.98MM |
| Interest Expense | $6.73MM | $6.76MM | $6.79MM |
| R&D Expense | $46.60MM | $54.89MM | $61.55MM |
| Income(Loss) | $294.30MM | $-4.37MM | $30.86MM |
| Taxes | $1.14MM | $2.02MM | $3.55MM |
| Profit(Loss)* | $293.16MM | $-6.39MM | $27.31MM |
| Stockholders Equity | $581.01MM | $622.07MM | $596.80MM |
| Inventory | $59.45MM | $53.29MM | $70.05MM |
| Assets | $985.85MM | $997.10MM | $986.26MM |
| Operating Cash Flow | $62.72MM | $100.56MM | $66.51MM |
| Capital expenditure | $7.14MM | $4.10MM | $6.35MM |
| Investing Cash Flow | $-316.00MM | $-153.93MM | $-18.04MM |
| Financing Cash Flow | $19.52MM | $1.39MM | $-102.02MM |
| Earnings Per Share** | $2.32 | $-0.05 | $0.21 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.